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MODELING CARDIOVASCULAR HEALTH OUTCOMES
IN MEDICAID HYPERTENSIVE PATIENTS—EFFECT OF
PATIENT ADHERENCE
Gu A, Shaya FT,Weir MR
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: The extent to which adherence to anti-
hypertensive medications may affect risk of having new cardio-
vascular events remains unclear, in part due to the methodological
complexity in measuring adherence. We sought to determine the
relationship between anti-hypertensive drug adherence and car-
diovascular health outcomes in a Medicaid, high risk population.
METHODS: The study is composed of continuously enrolled
patients in a Mid-Atlantic Medicaid Managed Care program
between July 1, 2002 and June 30, 2005, with at least three
prescriptions of anti-hypertensive medications and no such pre-
scription during the preceding six months. Adherence to anti-
hypertensive medications was ﬁrst measured as a time weighted
average of Cumulative Medication Acquisition (CMA) and then
as Medication Possession Ratio (MPR), with weight being the
length of therapeutic period of each drug class. We used Cox
proportional hazard models to assess the impact of adherence on
events of interest, adjusting for sociodemographic and clinical
characteristics. RESULTS: A total of 7939 patients qualiﬁed for
the study and 140 cardiovascular events were observed after six
months post index date. For theCMAmodel, we found every 10%
increase in CMA score decreased the hazard of having cardiovas-
cular events by approximately 14% and similar trend was
observed in theMPRmodel. Both of the effects were signiﬁcant at
P = 0.05 level. We also conducted sensitivity analyses by altering
washout-out period to three months and similar results
were observed. To disentangle the possible “healthy adherer”
effect, we investigated the relationship between CMA and risk of
hospitalization for Lung Cancer, HIV/AIDS, or Peptic Ulcer and
found no association between adherence and speciﬁed health
outcomes.CONCLUSIONS: In thisMedicaid population, a lower
risk of cardiovascular events associated with improved drug
adherence was observed. Adherence outcome beneﬁts are likely to
be mediated by drug effects and do not merely reﬂect a “healthy
adherer” behavior attributes.
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OBJECTIVE: Adherence to cardiovascular (CV) medications is
poor. Studies that investigate interventions to improve adherence
rarely consider the costs of these programs. We assessed the
effectiveness and costs of different adherence-improving interven-
tions for CV drugs. METHODS: We reviewed MEDLINE to
update a published literature review of interventions to improve
adherence to lipid-lowering and/or antihypertensive therapy. The
prior review covered January 1972–June 2002; this review
covered July 2002–October 2007. Search terms included hyper-
tension, hyperlipidemia, antihypertensive agents, antilipidemic
agents, patient compliance, intervention studies and reminder
system. Eligible studies evaluated at least one adherence interven-
tion, compared an intervention to control, used an adherence
measure other than self-report, and followed patients for >=6
months. Interventions were classiﬁed as dosing modiﬁcations,
patient education, case management, reminders, other interven-
tions, or combinations. Effectiveness was calculated as the ratio of
adherence in the intervention group to the control group. Costs
were based on those reported in the analysis, where available, or
estimated based on resource use described in the article. All costs
were standardized to 6 months and adjusted to 2006 dollars using
the medical component of the CPI. RESULTS: We identiﬁed 755
new articles, 5 of which met all eligibility criteria; when combined
with the prior review, there were a total of 23 interventions from
14 studies. Relative improvement (RI) in adherence ranged from
1.11 to 4.65. Six month intervention costs ranged from $9.59 to
$142.22 per patient. Reminders tended to have the lowest effec-
tiveness (RI: 1.11–1.14), but were the least costly ($9.59/6
months). Case management was the most effective (RI: 1.23–
4.65), but more costly than other interventions ($89.90–
$129.78/6 months). CONCLUSION: In general, there was a
positive association between the cost of the intervention and its
effectiveness at improving adherence. Understanding the costs and
beneﬁts of adherence interventions may guide design and imple-
mentation of efﬁcient adherence-improving programs.
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USING A LONGITUDINAL MODELTO ANALYZE DRUG
COMPLIANCE
Gause D, Lau H
Novartis Pharmaceuticals, East Hanover, NJ, USA
To describe a measure of drug compliance on each patient at
multiple time points, and illustrate an approach for quantifying
the impact of covariates on these longitudinal compliance mea-
surements. Nine thousand hypertensive patients from MED-
STAT’s Marketscan database were identiﬁed who ﬁlled an
antihypertensive drug 5 times in 2006. At each ﬁll, days since
expiration of previous ﬁll’s days supply (gap) was measured,
a smaller gap suggesting better compliance. Also measured were
covariates such as demographics, co-medication, and co-pay. A
random effect model was used to describe the dependence of the
ﬁve gap compliance measurements on each patient, with a
random intercept reﬂecting the impact of both measured and
unmeasured covariates. Patient speciﬁc slopes were used to
reﬂect relationships between gap and covariates. The average gap
was 5 days and the fraction of total gap variance due to hetero-
geneity across patients was 27%. The gap within patients
increased on average over time (0.5 day increase in gap size per
month) but this varied considerably between patients (SD = 0.8).
The gap was larger for diuretic than for non-diuretic drug users,
decreased slightly with age, and was not associated with co-pay.
Unlike single measures of compliance, longitudinal measures
provide opportunity to describe patterns over time within
patients, and permit impact of changing covariates within
patients to be estimated.
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IMPACT OF PRESCRIPTION COPAY ON ADHERENCEWITH
RENIN-ANGIOTENSIN SYSTEM AGENTS IN HEART FAILURE
PATIENTS
Ye X1, Sun SX1, Lee KY1, Dupclay L2, Plauschinat C2
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OBJECTIVE: The purpose of the study was to investigate the
relationship between prescription copay and adherence with
renin-angiotensin system (RAS) therapy in heart failure patients.
METHODS: Data for this study came from a large national
pharmacy beneﬁt manager’s clients. A retrospective data analysis
was used to identify patients who had a diagnosis of heart failure
(ICD-9 code 428) between July 1, 2003 and June 30, 2006. The
discharge date of the ﬁrst hospitalization after the 6-month base-
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